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Inﬂammationis a defensiveprocess againsttissue injury. Once thisself-protective strategy is initiated, an eﬀective resolution of the
process is crucial to avoid major and unnecessary tissue damage. If the underlying event inducing inﬂammation is not addressed
andhomeostasisisnotrestored, thisprocess canbecome chronic andlead to angiogenesisandcarcinogenesis.Thrombospondin-1
(TSP-1) is a matricellular protein involved in angiogenesis, cancer, and inﬂammation. The eﬀects of TSP-1 have been studied in
manypreclinicaltumormodels,andmimeticpeptides arebeingtestedincancerclinicaltrials.However,themolecularmechanisms
explaining its role in inﬂammatory processes are not well understood. This paper will discuss the role of TSP-1 in inﬂammation
and its interaction with key receptors that may explain its functions in that process. Recent literature will be reviewed showing
novel mechanisms by which this multifaceted protein could modulate the inﬂammatoryprocess and impact its resolution.
1.Introduction
Thrombospondin-1 (TSP-1) is a matricellular glycoprotein
ﬁrst discovered in activated platelets. [1] TSP-1 is the best-
studiedmemberofthethrombospondin (TSP)family, which
consistsofﬁveextracellularcalcium-bindingmultifunctional
proteins: TSP-1, TSP-2, TSP-3, TSP-4, and TSP-5. TSP-1
and TSP-2 are structurally similar, and they are expressed
on the cell surface during physiological events. A variety
of normal cells, including endothelial cells, ﬁbroblasts,
adipocytes, smooth muscle cells, monocytes, macrophages,
and transformed cells such as malignant glioma cells, secrete
TSP-1 [2, 3].
TSP-1 binds to protein components of the extracellular
matrix, such as ﬁbronectin. By this way, TSP-1 is stored
in the extracellular matrix where it folds and changes its
conformation. TSP-1-speciﬁc domains bind to proteogly-
cans, membrane proteins such as integrins, and other matrix
proteins expressed by a variety of cells [4, 5].
TSP-1 contains an N-terminal globular domain that
binds heparin, the type I, type II, and type III repeats,
and a terminal globular domain. The structure of TSP-
1 is schematically shown in Figure 1.T h eN H 2-terminal,
heparin-binding domain of TSP-1 interacts with low-density
lipoprotein receptor-related protein (LRP1). LRP1 releases
any metalloproteases already bounded to TSP-1, modulating
t h ep r o t e a s ea c t i v i t y[ 6]. This TSP-1 domain also binds
heparin sulfate proteoglycans and a number of integrins
that have an important function in angiogenesis, chemotaxis
adhesion, and cell motility [7]. All ﬁve members of the TSP
family have the repeat domains type II and III, but only TSP-
1andTSP -2containthetypeIr epeats[8].TypeIrepeats,also
called thrombospondin structural homology repeats (TSRs),
inhibit angiogenesis by activating CD36 and inducing apop-
tosis in endothelial cells [9]. CD36 (also known as fatty acid
translocase, FAT) is a glycosylated protein member of the
classBscavengerreceptorfamily.Itplaysanimportantrolein
multipleprocessessuchasfattyacidandglucosemetabolism.
CD36 is found on the surface of diverse cell types and
binds to many ligands, including TSP-1 [10, 11]. It has been
reported that upon binding with TSP-1, CD36 dimerizes,
becoming actively involved in signal transduction [12].
However, activation of CD36 as a monomer has also been
reported [13] .T h ea d h e s i v ea n da n t i a n g i o g e n i cf u n c t i o n so f
TSP-1 have been mainly attributed to its interaction with
CD36. Other domains of TSP-1 can, however, impact these
functions by interacting with other key receptors as it will be
discussed in succeeding sections.2 Mediators of Inﬂammation
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Figure 1: Schematic representation of the structure ofTSP-1and its receptor sites. TSP-1is a large, homotrimericmolecule (420kDa).Each
monomer consists of an interchain disulﬁde bond (S=S), procollagen homology domain (PC), Type I, II, and III repeats. The amino and
carboxyl terminals are globular [8]. RFK and RGDA are the binding sites for TGFβ and the integrins, respectively. CSVTCG is the receptor
site for CD36. The C-terminal domain of TSP-1 binds CD47. TSP-1 mimetic peptides have been designed from the heptapeptide GVITRIR
of the second type-1 repeat. ABT-526 and ABT-510 are nonapeptides and enantiomers of each other, where D-Ile was replaced with D-allo-
Ile in ABT-510 [33]. Sar, Nva, and NHEt are abbreviations for sarcosine, norvaline, and ethylamide. A second generation mimetic peptide,
ABT-898, has been reported to have increased potency and slower clearance [95]. These peptides have been used in clinical studies for their
antiangiogenic properties. Recombinant fragment rTSP1793–824 has been studied in experimental erosive arthritis [72].
TSP-1 is a major activator of transforming growth
factor (TGFβ1) [14]. Indeed, it is the only member of
the thrombospondin family that activates TGFβ1. TGFβ1
mediates wound healing, cell proliferation, extracellular
matrix formation, and the immune response. This multi-
functional cytokine is secreted to the extracellular matrix in
itsinactiveform,byvirtueofitsnoncovalentassociationwith
the latency-associated peptide (LAP) [15]. The activating
function of TSP-1 is due to the amino acid sequence RFK
located in the TSR [14–16]. TSP-1 releases TGFβ1f r o mi t s
latent form when it interacts with the N-terminal region of
LAP and binds the mature TGFβ1. This interaction results
in the formation of a complex that involves conformational
changes in TGFβ1, [16] making it accessible to its receptor.
LAP is crucial for TGFβ1 activation and regulates many of its
functions; additionally, LAP has functions in inﬂammation
independently of TGFβ1, such as the induction of chemo-
taxis of monocytes to injured tissues [17].
The type 3 repeats of TSP-1 are calcium-binding do-
mains. They contain amino acid sequences that interact with
the neutrophil elastase, and upon this binding these repeats
activateneutrophils[18,19].These type3repeatsalsoinhibit
the binding of ﬁbroblast growth factor to endothelial cells,
reducing angiogenesis [20].
The COOH-terminal domain of TSP-1 binds to CD47,
also known as integrin-associated protein. [21]T h i sd o m a i n
also interacts with integrins such as β1a n dβv6 integrins
and actively binds to proteoglycans allowing cell adhesion
and spreading [7]. These and other interactions signiﬁ-
cantly aﬀect angiogenesis, cell proliferation, and immune
responses. TSP-1 binding with CD47 also regulates nitric
oxide (NO), a biogas, quite important in both normal
and pathological events [22]. By modulating the eﬀects of
NO, the carboxy-terminal domain of TSP-1 has important
function in vasodilation and chemotaxis [22]. CD47 impacts
angiogenesis to a large extent. This receptor inhibits NO
as well as all its vascular functions even when TSP-1 is
present at very low (physiological) concentrations [22].
Analysis of wound bed vascularity at 72 hours after skin
grafting from TSP-1 and CD47 null mice shows signiﬁcant
increased numbers of blood vessels [23]. Most recently it
has been reported that CD47 associates with the receptor of
vascular endothelial growth factor, VEGFR2 [24]. However,
the binding of CD47 with TSP1 or other ligands inhibits
VEGFR2 phosphorylation and further angiogenesis.
This paper focuses on well-known interactions of TSP-
1 with key receptors and growth factors during the initial
inﬂammatory events throughout the chronic inﬂammatory
processes. New developments are also herein discussed,
showing the involvement of TSP-1 in pivotal transcrip-
tional pathways related to inﬂammation and inﬂammation-
induced carcinogenesis.
2.TSP-1inAcuteInﬂammation
Inﬂammation is the reaction of living tissue to local injury.
The inﬂammatory acute process begins when cells sense the
injury, and they release chemical mediators called cytokines.
Local macrophages express surface membrane receptors
called toll-like receptors (TLR) that recognize speciﬁc types
of antigens. Once activated, TLR triggers the release of more
cytokines promoting inﬂammation and attracting white
blood cells. Cytokines will promote leukocytosis by inducing
factors favoring the rapid release of neutrophils from the red
bone marrow. Neutrophils enter the blood stream, and by
diapedesis they emigrate outside the blood vessels.
T h ev a s c u l a rs y s t e mi sak e yf a c t o ri na c u t ei n ﬂ a m m a -
tion. Vasodilation increases the capillary permeability and
promotes exudate formation. The slow blood ﬂow favors
the release of chemical mediators and enhances local edema.
Chemotactic agents accelerate the migration of leukocytes
to the site of injury such as monocytes, which later become
macrophages, engulﬁng any on-site cell debris or pathogens.
In addition, mast cells (producing histamine), injured tissueMediators of Inﬂammation 3
cells,phagocytes,lymphocytes,basophils,andbloodproteins
are all sources of inﬂammatory mediators.
TSP-1 is transiently released early during the acute phase
of inﬂammation, and multiple factors seem to modulate
the release of TSP-1 during this process. TSP-1 is strongly
expressed in neutrophils, inducing an intense chemotactic
response to injured tissues [2]. TSP-1 is secreted in response
to inﬂammation, promoting the resolution of the inﬂam-
matory process and facilitating phagocytosis of damaged
cells [25, 26]. Thus, enhanced production of TSP-1 could
be a compensatory mechanism for controlling the immune
response and protecting tissues from excessive damage.
TSP-1 mediates macrophage phagocytosis of apoptotic
cells via CD36. This receptor is coexpressed with TSP-1 in
macrophages and endothelial cells, and, by binding with
CD36(Figure 2),TSP-1inducesapoptosisinendothelialcells
[9]. By activating CD36, TSP-1 also controls blood ﬂow
and leukocyte inﬁltration modulating the action of the NO
pathway in injured tissues [27]. NO is a gas produced when
L-arginine is converted to L-citruline by the enzyme nitric
oxide synthase (NOS). There are four diﬀerent isoforms of
NOS, neuronal (nNOS), endothelial (eNOS), mitochondrial
(mtNOS), and the inducible isoform (iNOS). The ﬁrst two
are secreted during normal physiological events, but only
iNOS is expressed upon inﬂammatory stimuli [28].
The eﬀects of NO in inﬂammation have been extensively
recognized in a variety of studies. NO can modulate
leukocyte adhesion in a dose-dependent manner [27]. At
low doses, NO is anti-inﬂammatory and antiangiogenic
but, after inﬂammatory stimuli, high levels of NO are
secreted promoting angiogenesis and leukocyte adhesion
to the endothelium [29]. TSP-1 could inhibit the soluble
guanylyl cyclase system in endothelial cells and consequently
the activation of NO by interacting with CD36 and CD47
[22]. Through this mechanism, TSP-1 inhibits inﬂammation
by blocking adhesion and activation of leukocytes to the
endothelium and diminishing angiogenesis [22, 30, 31].
Another factor interacting with TSP-1 during early
inﬂammation is the peroxisome proliferator-activated recep-
tor (PPAR). PPAR is a member of the nuclear hormone
receptor superfamily of transcription factors. When PPAR
is absent in leukocytes, the leukocytes secrete high levels of
TSP-1 [32]. PPARγ greatly enhances the proapoptotic eﬀects
of the TSP-1-derived peptide ABT510 (Abbott Laboratories)
[33, 34]. This peptide corresponds to the TSR of TSP-1
and induces vascular apoptosis in vitro and in vivo through
its interaction with CD36 [35]. By using a PPARγ agonist,
the expression of CD36 in endothelial cells is enhanced,
improving the antiangiogenic eﬀects of ABT510 in a CD36-
dependent manner [34].
The TSP-1 receptor CD47 is critical for the migration of
leukocytes through endothelial and epithelial barriers [36].
CD47 is strongly expressed in polymorphonuclear cells, and
its activation enhances the expression of TSP-1 in leukocytes
[37]. TSP-1 also induces leukocytic apoptosis through the
CD47 pathway. CD47 can directly cause apoptosis through
mitochondrialmechanisms, orbyactivationoftheFas/CD95
pathway [38]. Expression of CD47 in apoptotic granulocytes
can inﬂuence the phagocytic functions of the macrophages
in inﬂammatory sites suggesting a critical role of this factor
in the resolution of the process [39]( Figure 2).
3.TSP-1inChronic Inﬂammationand
AdaptiveImmunity
Acute inﬂammation could advance to a resolution, progress
to the formation ofan abscess, walling oﬀ by ﬁbrotic capsule,
or evolve as scar upon tissue destruction, ﬁbrin and collagen
deposition. In many instances, this process continues as
chronic inﬂammation. Chronic inﬂammation is character-
ized by inﬁltration of mononuclear cells, macrophages, lym-
phocytes,and plasma cells. Chronically inﬂamed tissueshave
ﬁbroblast proliferation, angiogenesis, tissue destruction, and
ﬁbrosis.
Monocytes and macrophages are keyelements of chronic
inﬂammation. They invade the injured area during the acute
process but, if the cause is not eliminated, inﬁltration by
macrophagespersistsforlongperiodsoftime.Thecontinued
secretion of chemotactic factors allows the constant supply
of monocytes from the blood and their conversion to
macrophages. These cells are key for further lymphocyte
inﬁltration, ﬁbroblast proliferation, tissue destruction, and
ﬁbrosis. Lymphocytes arise from the hemoblasts of the
bone marrow, and later they develop immunocompentence
and self-tolerance. T lymphocytes mature in the thymus
and confer cell-mediated immunity. Plasma cells or B
lymphocytes produce antibodies against antigens persisting
in the area and therefore provide humoral immunity. They
become immunocompetent when antigen-speciﬁc receptors
appear on their surface. Plasmatic cells and macrophages
are called antigen-presenting cells (APCs). Included in this
group are dendritic cells (DCs), which internalize antigens
and present antigenic determinants on their surface for
recognition by T lymphocytes. They are part of the adaptive
immune system that recognizes something as foreign and
acts to immobilize and remove it. During the early stages
of injury and inﬂammation, high levels of TSP-1 increase
the tolerance of DC to antigens, ending the inﬂammatory
response. TSP-1 can modulate inﬂammation by inhibiting
or enhancing the secretion of the cytokine interleukin 10
( I L 1 0 ) ,b yt h i sw a y ,T S P - 1c a na l s or e g u l a t et h ef u n c t i o n s
of DC [26]. In addition, after adding IL-6, IL-10, or TGFβ1
to cultured DC, they become immune tolerant and show
upregulation of intracellular TSP-1 [40]. TSP-1 also inhibits
thefunctionofAPCbysuppressing theircapacitytosensitize
T-cells in the host. This is demonstrated in a corneal
transplantation model, in which most of the corneal TSP-
1 null allografts are rejected [41]. CD47 has also a crucial
role in T-cell activation [42, 43]. Interaction of TSP-1 with
CD47 promotes the activation of thymus-derived CD4+
CD25+ T regulatory cells (Tregs). Through this mechanism,
CD47helpstomaintainself-toleranceinducingasuppressive
phenotype [25].
It has been recently reported that bacterial pathogen-
esis may be mediated by CD47. Suppression of CD47 or
TSP-1 expression in DC by using small interfering RNA
(siRNA) technique actually protects newborn mice against4 Mediators of Inﬂammation
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Figure 2: Dual role of CD-36—TSP-1 interaction in inﬂammation. Expression of CD36 is positively regulated by PPARγ and negatively
regulated by TGFβ. As an integral membrane protein, CD36 binds many ligands including TSP-1. The CD36-TSP-1 interaction involves
conformationalchanges in TSP-1. This interaction mediates apoptotic eﬀects via the CD47-dependent pathway, which has multiple eﬀects.
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Figure 3: The homotrimeric TSP-1 activates latent TGFβ1 by binding the N-terminal propeptide LAP and the mature TGFβ1. The binding
results in conformational changes in TGFβ1 and allows TGFβ1 to be recognized by its receptor. Mature, active TGFβ1 has been reported to
decrease dendritic cell maturation and activate T cells. An opposing role of TGFβ1 results in ﬁbrosis.
bacterial (Escherichia coli)m e n i n g i t i s[ 44]. Again, the loss of
CD47 activity prevents the maturation of the DCs and the
production of inﬂammatory cytokines [44]. In conclusion,
CD47 seems to have pivotal functions in inﬂammation and
provides a major mechanistic pathway for the functions of
TSP-1 in that process.
Finally, the deﬁciency of CD36 enhances the severity
of bacterial and malaria infection. Cd36−/− mice exhibit
an impaired early proinﬂammatory response to infection,
elevation of cytokines, and higher mortality [45, 46]. These
ﬁndingssuggestthatCD36isquitecriticalfortherecognition
and clearance of pathogens in acute and chronic infections.
By binding to this receptor, TSP-1 could modulate the
inﬂammatory process by activating macrophages and favor-
ing phagocytosis. During chronic inﬂammation, these adap-
tive immune mechanisms provide defense against disease
and are regulated by cellular interactions and cytokines. B
lymphocytes secrete antibodies that bind to infectious agents
and label them for destruction or elimination. Once inside a
cell, a pathogen becomes inaccessible to those antibodies and
cytotoxicTcellscoulddestroy themby inducingapoptosis of
the cell host. Regulatory T cells can modulate the secretionMediators of Inﬂammation 5
of cytokines enhancing the functions of macrophages and B-
lymphocytes. TSP-1 has been reported to decrease immune
responses by inhibition of T-cell eﬀectors, or by directly
inducing T cell apoptosis [47, 48]. In addition, by binding
to α4β1 integrin TSP-1 promotes T-cell adhesion and
chemotaxis [43].
TGFβ1 activation is a crucial element in intestinal home-
ostasis [49]. In the intestinal tract, an abnormal response to
the normal gut ﬂora is a characteristic of the pathogenesis
of inﬂammatory bowel disease (IBD). Mucosal T cells from
patients with IBD express high levels of Smad7, an inhibitor
of TGFβ1 signaling. By this mechanism, TGFβ1m e d i a t e s
intestinal healing and susceptibility to injury [50–53]. How-
ever, by activating TGFβ1, TSP-1 also enhances ﬁbrosis and
compromises organ function [54, 55]( Figure 3). During
the immune response, leukocytes produce reactive oxygen
species (ROS) that include free radicals and peroxides. ROS
are quite important for the killing of pathogens, but they
can also producecell damage. TGFβ1f a v o r st h ef o r m a t i o no f
ROS,and, as acycle,ROScan also activate TGFβ1pr omoting
apoptosis and ﬁbrosis [56].
Angiogenesis is an active component of chronic inﬂam-
matorydiseases suchasrheumatoidarthritis, atherosclerosis,
diabetic retinopathy, airway inﬂammation, and others [57].
TSP-1 exerts a powerful antiangiogenic eﬀect, and this
function has a signiﬁcant impact in chronic inﬂammation.
Activated endothelial cells secrete cytokines, chemokines,
matrix metalloproteinases, and growth factors that can
greatly inﬂuence the inﬂammatory reaction and promote
carcinogenesis.
4.TSP-1inInﬂammatory Diseasesand
Animal Models
TSP-1 deﬁcient mice display extensive acute pneumonia,
leukocytosis, pancreatitis, and inﬂammatory inﬁltrates in
the lacrimal glands [26, 58, 59]. This phenotype suggests
that TSP-1 has a signiﬁcant role in inﬂammation, a role
that has not been exhaustively analyzed. TSP-1 has anti-
inﬂammatory and proinﬂammatory eﬀects observed in sev-
eral diseases and animal models. These contrasting functions
in inﬂammation are possible due to interactions with
multiple receptors or to the presence of speciﬁc matricellular
proteins in injured tissue. In addition, TSP-1 might act by a
biphasic or dose-dependent mechanism.
TSP-1 enhances ﬁbrosis and renal damage by its interac-
tion with TGFβ1[ 54], while LSKL, a peptide antagonist of
TSP-1, reduces renal interstitial ﬁbrosis in a rat experimental
model of kidney disease [60]. This eﬀect is attributed to
the competitive properties of LSKL that prevents TSP-1-
mediated activation of TGFβ1[ 60].
TSP-1 is also expressed in glomerulopathies and is
considered an early marker of inﬂammation and ﬁbrosis
[61]. The developmentof diabetic nephropathy isattenuated
in TSP-1-deﬁcient mice as demonstrated by a signiﬁcant
reductionof glomerulosclerosis, glomerular matrix accumu-
lation, podocyte injury, renal inﬁltration with inﬂammatory
cells, and alterations of renal functional parameters [62].
As an activator of TGFβ1, TSP-1 could modulate the
functions of TGFβ1 in cardiovascular diseases, atheroscle-
rosis, and obesity. Inﬂammatory cells secrete TSP-1 during
the acute phase of the healing process in myocardial infarc-
tion. Infarcted murine hearts show marked upregulation of
TGFβ1. In addition, TSP-1 is selectively expressed in the
infarcted border suggesting that TSP-1 might inhibit the
expansion of the inﬂammation by activating TGFβ1[ 63].
In the inﬂammatory processes leading to atherosclerosis,
TSP-1 deﬁciency enhances inﬂammation by accelerating
plaque maturation and necrosis in ApoE-deﬁcient mice.
ApoE−/−TSP-1−/− mice also show enhance expression of
metalloproteinase 9. A defective phagocytosis appears to
accelerate necrosis favoring additional inﬂammation and
macrophage inﬁltration [64]. However, TSP-1 expression is
increased in response to high glucose in the wall of large
vessels and accelerates atherosclerosis and other pathological
events observed in diabetes [65].
TSP-1 mRNA is signiﬁcantly associated with obesity and
insulin resistance in nondiabetic patients. This correlation
is explained by the TSP-1-dependent TGFβ1a c t i v a t i o nt h a t
leads to upregulation of plasminogen activator inhibitor 1
(PAI-1) gene expression. Elevated circulating PAI-1 levelsare
detected in insulin resistance and metabolic syndrome [66].
Mice lacking TSP-1 or the integrin β6 subunit (TSP-
1−/− and Itgb6−/− mice, resp.) develop inﬂammation with
a phenotype similar to that seen in TGFβ1n u l lm i c e .T h e
inﬂammation is not as severe as the one found in Tgfb1−/−
mice, which develop marked inﬁltrates of activated T cells in
multiple organs and die soon after weaning [51].
TSP-1 null mice have a more severe course of acute
induced colitis; they display increased bleeding and colonic
inﬂammation compared to WT mice controls [67]. TSP-1
deﬁciency signiﬁcantly enhances angiogenesis and dysplasia
when the disease is cyclically induced. TSP-1-deﬁcient mice
under multiple cycles of 2.5% of dextran sodium sulfate for
inductionofcolitisdiebeforethecyclesare completed.These
mice show high incidence of megacolon and peritonitis due
to the deeper inﬁltration of leukocytes into the muscularis
and intestinal perforation. In order to increase survival,
doses need to be signiﬁcantly reduced [68]. The use of the
TSP-mimetic peptide ABT510 drastically reduces intestinal
inﬂammation and angiogenesis and enhances the expression
ofCD36,which suggeststhat CD36modulatesinﬂammation
in this model [67]. Additionally, the interaction of TSP-1
with the NO pathway seems to be involved in the antian-
giogenic mechanisms mediated by the ABT510 in cancers
[31, 69], and it might also explain the anti-inﬂammatory
eﬀects of this peptide in the colitis model [70]. Similarly,
in a rat model with bleomycin-induced lung injury, a CD36
peptide also decreases inﬂammation and ﬁbrosis in the lungs
[71].
AsyntheticpeptidederivedfromtheTSP-1type3repeats
(Figure 1) also diminishes inﬂammation and angiogenesis in
an experimental model of erosive arthritis [72]. This peptide
decreases angiogenesis, leukocyteinﬁltration, andthickening
of the synovial lining of the joint. In the spleen and liver, this
peptide signiﬁcantly reduces the formation of granulomas
[73]. However, TSP-1 is upregulated in monocytes, and6 Mediators of Inﬂammation
tissues from patients with rheumatoid arthritis (RA) [74,
75] and high plasmatic levels of TSP-1 are correlated with
proinﬂammatory cytokines in these patients [76].
TSP-1 also exerts proinﬂammatory eﬀects in certain
types of myositis [77, 78]. The chemotactic eﬀect of TSP-1
in leukocytes by its binding to CD47 perpetuates the muscle
inﬂammation in response to high levels of TNF-alpha.
In transplantation research, most of the corneal TSP-
1 null allografts are rejected, suggesting a protolerogenic
function [41, 79]. Interestingly, when TSP-1 is inhibited
by siRNA-transfection in pancreatic islet cells, improved
revascularization andfunction are observedinthepancreatic
grafts. Antiangiogenic compounds, such as TSP-1, might be
useful for achieving a better perfusion and oxygenation in
organ transplants [80].
5.TSP-1and TranscriptionalPathwaysLeading
to Inﬂammation-InducedCarcinogenesis
5.1. The Nuclear Factor Kappa-Light-Chain-Enhancer of Acti-
vated B Cells (NF-κB). The NF-κB is a transcription factor
present in almost all animal cell types. It is involved in
many biological processes such as inﬂammation, immunity,
diﬀerentiation, cell growth, tumorigenesis, and apoptosis.
Normally NF-κB is maintained in the cytoplasm by its
inhibitor (IκB). Phosphorylation and subsequent degrada-
tion of IκB releases NF-κB and allows it to be translocated
t ot h en u c l e u s .O n c ei n s i d et h en u c l e u s ,t h i st r a n s c r i p t i o n
factor induces its target genes, thereby inhibiting apoptosis,
promoting inﬂammation, angiogenesis, and carcinogenesis
[81]. Importantly, NF-κB activates the transcription of genes
such as TNF-alpha and IL-6, which have major roles in
regulating the immune response [82].
Recently,ithasbeenreportedthatblockingtheactivation
of NF-κB upregulates TSP-1 expression in rat granulation
tissue [83]. TSP-1 has a major role in wound healing, and
a signiﬁcant delay of the healing process is observed in TSP-
1−/− mice [84].
The link between TSP-1 and NF-κB seems to be closely
related to mechanisms of angiogenesis and carcinogenesis.
TSP-1 enhances the binding of NF-κBt oD N Ai n h i b i t i n g
angiogenesis, and these events are reverted by blocking the
NF-κBp a t h w a y[ 85]. Activation of NF-κBb yo x i d i z e dl o w -
density lipoprotein (oxLDL), a speciﬁc ligand of CD36, is
reduced in macrophages of patients with CD36 deﬁciency
[86]. TSP-1 might activate this pathway by its interaction
with this receptor.
Studies in prostate cancers indicate that the combined
decrease of NF-κB and increase of TSP-1, modulated by the
expression of the androgen receptor, exert antitumor eﬀects
[87]. The TSP-1-derived peptide angiocidin has antitumor
eﬀects and induces the diﬀerentiation of monocytes to
macrophages by activating the NF-κBp a t h w a y[ 88].
5.2. The Signal Transducer and Activator of Transcription
3( S T A T 3 ) .In response to cytokines and growth factors,
members oftheSTATfamily arephosphorylated byreceptor-
associated kinases forming homo- or heterodimers. These
factors translocate to the nucleus where they act as tran-
scription activators. The lack of STAT3, the most important
member of this family, actually leads to embryonic lethality
[89]. STAT3 mediates the expression of a variety of genes
in response to cell stimuli and thus plays a key role in
many cellular processes such as cell growth and apoptosis.
The binding of IL-6 to the gp130 receptor triggers the
phosphorylation of STAT3 by JAK2 [90, 91].
It has been reported that downregulation of TGFβ1i n
epithelial cells inhibits the secretion of IL-6. By this mech-
anism, blocking TGFβ1 inhibits the IL-6/STAT3 signaling
preventing colorectal cancer [92]. Furthermore, activated
STAT3 has been recently reported as crucial for intestinal
carcinogenesis in colitis-associated cancer [93]. In addition,
protein proﬁling of head and neck squamous carcinomas
shows a signiﬁcant decrease of several proteins such TSP-1
and TGFβ1 with concomitant increase of STAT3 [94].
In a model of angiogenesis, higher levels of IL-6 are
secreted by TSP-1−/− aortic explants, and similar results are
found in a mouse model of colitis [95]. The higher levels
of IL-6 are lowered upon activation of TGFβ1o n l yi nW T
aortas.TheactivityofIL-6was speciﬁcallyexaminedthrough
the STAT3 pathway in colonic tissues evaluating the status of
thephosphorylatedformsofSTAT3(p-STAT3).Interestingly,
p-STAT3 expression is highly expressed in TSP-1−/− colons
and almost abolished in colons from mice treated with a
new TSP-1-mimetic ABT-898 (Abbott Laboratories) [96].
These data suggest that this mimetic peptide directly binds
to TSP-1 receptors such as CD36 or indirectly interacts with
other membrane domains to downregulate STAT3 pathway,
thereby depressing the immune response [95].
TheexpressionofcytokinessuchasIL-6andTNFαisalso
regulated by NF-κB. Therefore, activation of this pathway
is critical for further activation of STAT3 in colitis [97].
These data indicate a cross talk between NF-κBa n dS T A T 3
in inﬂammation and cancer. Therefore, linking TSP-1-
mediated mechanisms to these fundamental transcriptional
pathways warrants further investigation.
6.Conclusion
TSP-1 interacts with a variety of factors in a synergistic way,
playing a crucial role in many stages of the inﬂammatory
response. We discussed herein the interactions of TSP-1
with well-known partners such as CD36, CD47, NO, and
TGFβ1. We also reviewed recent developments explaining
how TSP-1 and its derived peptides directly or indirectly
regulate inﬂammatory events in animal models and human
diseases.
TSP-1 is generally found elevated in inﬂammatory pro-
cesses and in several instances is proinﬂammatory. Leuko-
cytes migrate to areas of injury or infection in elevated
numbers; similarly, TSP-1 is secreted at high levels in some
areas in order to activate speciﬁc mechanisms for regulating
the inﬂammatory response. In some cases, TSP-1 activates
leukocytes, enhances chemotaxis, and accelerates ﬁbrosis.
In other instances, TSP-1 prevents injury and progressive
damage and enhances homeostasis.Mediators of Inﬂammation 7
Finally,newinsightsaboutkeysignalingpathwayssuchas
NF-κB and STAT3 were discussed. Because chronic inﬂam-
mation is linked with tumor development, further studies
analyzing the role of TSP-1 in these pathways could elucidate
the similar contradictory functions of TSP-1 in cancer.
The unraveling of these mechanisms will make possible
the development of new and more eﬀective therapies for
controlling inﬂammation and blocking carcinogenesis.
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